New Lassa Vaccine Trial in Nigeria

The International AIDS Vaccine Initiative (IAVI) was awarded €22.8 million by the European & Developing Countries Clinical Trials Partnership and the Coalition for Epidemic Preparedness Innovations (CEPI) to conduct a Phase IIb clinical trial of IAVI’s Lassa fever vaccine candidate among adults and children in Liberia, Nigeria, and Sierra Leone.  The vaccine candidate uses a ...
Read More»
Show More ∨